Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other financing activities (2020 - 2024)

Keros Therapeutics posted quarterly Other financing activities of $130000.0 for Q3 2024, up 381.48% year-on-year from $27000.0 in Q4 2023, and up 94.03% on a QoQ basis from $67000.0 in Q4 2023.

Keros Therapeutics (KROS) has 4 years of Other financing activities data on file, last reported at $130000.0 in Q3 2024.

  • For the quarter ending Q3 2024, Other financing activities rose 381.48% year-over-year to $130000.0; the trailing twelve-month figure through Dec 2025 stood at $130000.0 (down 41.96% YoY), and the FY2024 full-year result was $171000.0, up 81.91% from the prior year.
  • Other financing activities for Q3 2024 stood at $130000.0, up from $67000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $219000.0 in Q1 2020 and bottomed at $8000.0 in Q2 2020.
  • The 4-year median for Other financing activities is $100000.0 (2021), against an average of $106285.7.
  • The widest annual swing landed in 2021, when Other financing activities slumped 48.19%; it then jumped 381.48% in 2024.
  • A 4-year view of Other financing activities shows it stood at $193000.0 in 2020, then plunged by 48.19% to $100000.0 in 2021, then tumbled by 33.0% to $67000.0 in 2023, then soared by 94.03% to $130000.0 in 2024.
  • The last three Other financing activities figures came in at $130000.0 (Q3 2024), $67000.0 (Q4 2023), and $27000.0 (Q3 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Keros Therapeutics 403.85 Mn 116.45 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2024 130,000.00
Sep 30, 2024 130,000.00
Dec 31, 2023 67,000.00
Dec 31, 2023 67,000.00
Sep 30, 2023 27,000.00
Sep 30, 2023 27,000.00
Dec 31, 2021 100,000.00
Dec 31, 2021 100,000.00
Dec 31, 2020 193,000.00
Dec 31, 2020 193,000.00
Jun 30, 2020 8,000.00
Jun 30, 2020 8,000.00
Mar 31, 2020 219,000.00
Mar 31, 2020 219,000.00